Caddick Construction has started building "Project Vulcan Seals", an engineering research and development centre at Rotherham’s Advanced Manufacturing Park on behalf of sealing technology specialists, ...

After teasing at I/O 2024 and announcing this April, Google today is launching Workspace Studio as a new automation tool that lets you “design, manage, and share AI agents” powered by Gemini 3’s ...

Subscribers of Disney Plus will soon be able to generate videos for the platform using AI, according to CEO Bob Iger. He mentioned plans for such features in an earnings call for the year’s end, as ...

Bob Iger says AI will give viewers ‘the opportunity to create on our platforms.’ Bob Iger says AI will give viewers ‘the opportunity to create on our platforms.’ is a news writer who covers the ...

Disney has been taking action to protect its intellectual property from the ravages of generative artificial intelligence—but it’s also taking steps to harness generative AI for its own benefit. In an ...

Boy, Disney continues to be the villain. They have proven time and again that, despite their outward appearance of hopeful art for the whole family, the House of Mouse has but one priority and that is ...

PS Plus users on PS4 are reminded that they have another month left to enjoy the service as they know it. We’re expecting subscription discounts on Black Friday 2025, but those who don’t have a PS5 ...

On today’s Courtesy Desk, the WGN Morning News team is celebrating “National Create a Great Funeral Day” by planning out their funerals. Love the WGN Morning News? We love you, too. And you can have ...

It’s just Apple TV now, no plus. Apple has rebranded its six-year-old streaming service Apple TV+ to Apple TV — which is the same name as its connected smart TV device product and app. The tech ...

“OpenAds,” launched by The Trade Desk on Thursday, is described by the company as sort of a prebid wrapper designed to give ad buyers direct access to ad impressions from publishers. There will be one ...

Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multitarget drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.